Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A comparison of peak cough flow and peak expiratory flow in children with neuromuscular disorders.

Paediatric respiratory reviews·2024

Same author

Can postural changes in spirometry in children with Duchenne muscular dystrophy predict sleep hypoventilation?

Paediatric respiratory reviews·2023

Same author

Two fine-scale channels for encoding motion and stereopsis within the human magnocellular stream.

Progress in neurobiology·2022

Same author

Lightweight Smart Autofocusing Eyeglasses.

Proceedings of SPIE--the International Society for Optical Engineering·2020

Same author

Powered Air Purifying Respirators (PAPR) for the protection of surgeons during operative tasks: a user perspective assessment.

The British journal of surgery·2020

Same author

Surveillance of Salmonella spp. in the environment of public hospitals in KwaZulu-Natal, South Africa.

The Journal of hospital infection·2020

Search research articles

Related Experiment Video

Updated: May 21, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Emerging anticoagulants.

B Kennedy¹, F S Gargoum, L Kennedy

¹Department of Respiratory Medicine, Mercy University Hospital, Grenville Place, Cork, Ireland.

Current Medicinal Chemistry

|June 12, 2012

Summary

Novel anticoagulants, including factor Xa and thrombin inhibitors, offer improved safety and efficacy over traditional options like warfarin and heparin. These newer agents promise easier administration and predictable outcomes for preventing blood clots and stroke.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Experiment Videos

Last Updated: May 21, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

Pharmacology
Hematology
Cardiovascular Medicine

Background:

Traditional anticoagulants like warfarin and heparin have limitations including adverse effects and need for monitoring.
Advances in understanding hemostasis and the coagulation cascade have driven the development of novel anticoagulants.
Newer agents aim for improved safety, efficacy, pharmacodynamics, and ease of administration compared to older treatments.

Purpose of the Study:

To review emerging novel anticoagulants.
To discuss their applications in venous thromboembolism prophylaxis and treatment.
To explore their role in stroke prevention for nonvalvular atrial fibrillation and in coronary artery disease.

Main Methods:

Review of scientific literature on novel anticoagulant agents.
Analysis of pharmacokinetic and pharmacodynamic profiles.
Evaluation of clinical applications and comparative efficacy.

Main Results:

Development of direct and indirect factor Xa inhibitors (e.g., apixaban, rivaroxaban, fondaparinux).
Development of direct thrombin inhibitors (e.g., dabigatran etexilate, bivalirudin).
These novel agents offer rapid onset, stable profiles, and reduced monitoring needs.

Conclusions:

Novel anticoagulants represent a significant advancement over traditional therapies.
They provide effective options for venous thromboembolism, stroke prevention in atrial fibrillation, and coronary artery disease.
Further research and clinical adoption are expected to enhance patient outcomes.